Dynavax Hepatitis B Phase III Study Positive

By Douglas A. McIntyre Published Nov 30, 3:53AM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

From BioHealth Investor

Shares of Dynavax Technologies Corp (DVAX) jumped more than 30% on Wednesday after the company announced that its Hepatitis B phase III clinical study showed positive results. The announcement came following market close on Tuesday.

The study showed a statistically significant advantage of Dynavax’s HEPLISAV HEP B vaccine when compared to the conventional vaccine, Engerix-B, developed by GlaxoSmithKline (GSK).

What is of primary importance is the fact that HEPLISAV outperformed Engerix-B in older subjects, a population who has historically proven more difficult to immunize.

It was able to provide over 98% protection in this older population after only two doses.

Further trials of HEPLISAV are planned to take place in Canada and Europe to investigate multiple dosing regimens and the effects of the vaccine in differing age populations. Dynavax expects these trials to conclude in 2008.

Shares of Dynavax closed at $9.79 after establishing a new intraday 52-week high.

http://www.biohealthinvestor.com/

About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.